Pathogenic Interleukin-10 Receptor Alpha Variants in Humans - Balancing Natural Selection and Clinical Implications.

Dominik Aschenbrenner, Ziqing Ye, Ying Zhou, Wenhui Hu, Isabel Brooks, Isabelle Williams, Melania Capitani, Lisa Gartner, Daniel Kotlarz, Scott B Snapper, Christoph Klein, Aleixo M Muise, Brian D Marsden, Ying Huang, Holm H Uhlig

Journal: Journal of clinical immunology 2023;43(2):495-511

PMID: 36370291

Abstract

Balancing natural selection is a process by which genetic variants arise in populations that are beneficial to heterozygous carriers, but pathogenic when homozygous. We systematically investigated the prevalence, structural, and functional consequences of pathogenic IL10RA variants that are associated with monogenic inflammatory bowel disease. We identify 36 non-synonymous and non-sense variants in the IL10RA gene. Since the majority of these IL10RA variants have not been functionally characterized, we performed a systematic screening of their impact on STAT3 phosphorylation upon IL-10 stimulation. Based on the geographic accumulation of confirmed pathogenic IL10RA variants in East Asia and in Northeast China, the distribution of infectious disorders worldwide, and the functional evidence of IL-10 signaling in the pathogenesis, we identify Schistosoma japonicum infection as plausible selection pressure driving variation in IL10RA. Consistent with this is a partially augmented IL-10 response in peripheral blood mononuclear cells from heterozygous variant carriers. A parasite-driven heterozygote advantage through reduced IL-10 signaling has implications for health care utilization in regions with high allele frequencies and potentially indicates pathogen eradication strategies that target IL-10 signaling.

© 2022. The Author(s).

Address: Translational Gastroenterology Unit, Experimental Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.; Department of Gastroenterology, National Children's Medical Center, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China.; SenTcell Ltd., London, UK.; Dr. von Hauner Children's Hospital, Department of Pediatrics, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.; Institute of Translational Genomics, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.; Boston Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA.; Gene Center, LMU Munich, Munich, Germany.; Deutsche Zentrum für Infektionsforschung (DZIF) and Deutsches Zentrum für Kinder- und Jugendgesundheit, Partner site Munich, Munich, Germany.; SickKids Inflammatory Bowel Disease Centre and Cell Biology Program, Research Institute, The Hospital for Sick Children, Toronto, Canada.; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Toronto, Canada.; The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.; Centre of Medicines Discovery, NDM, University of Oxford, Oxford, OX3 7DQ, UK.; Kennedy Institute of Rheumatology, NDORMS, University of Oxford, Oxford, OX3 7FY, UK.; Department of Gastroenterology, National Children's Medical Center, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. [email protected].; Translational Gastroenterology Unit, Experimental Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK. [email protected].; Department of Pediatrics, University of Oxford, Oxford, UK. [email protected].; Biomedical Research Center, University of Oxford, Oxford, UK. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.